Skip to main content

Table 1 Comparative adverse events of different DMTs [7, 8]

From: Decision making under uncertainty, therapeutic inertia, and physicians’ risk preferences in the management of multiple sclerosis (DIScUTIR MS)

Disease modifying agent Adverse events
Interferon beta • Depression
• thrombotic microangiopathy
• hepatotoxicity
• ISRs
• Flu-like
• LFT elevation
• Leukopenia
Glatiramer acetate • ISRs
• Benign systemic reaction
Mitoxantrone • Cardiac toxicity
• Leukemia
Natalizumab • Infusion reactions
• PML
• Infusion-related fatigue
Fingolimod • Bradyarrhythmia
• Macular edema
• Herpes virus infection
• PML
• BCC
• LFT elevation
• Lymphopenia
• Mild hypertension
Teriflunomide • Hepatotoxicity
• Peripheral neuropathy
• Alopecia
• Nausea/Diarrhea
Dimethyl fumarate • Flushing
• Gastrointestinal
• PML
Alemtuzumab • Infusion reactions
• ITP
• Goodpasture syndrome
• Thyroid cancer
• Infections
• Autoimmune thyroid disease
  1. ISRs injection-site reactions, LFT liver function test, PML progressive multifocal leukoencephalopathy, ITP idiopathic thrombocytopenic purpura, BCC basal cell carcinoma